澳大利亚新南威尔士州直接抗病毒治疗时代丙型肝炎相关肝病负担下降
该研究基于澳大利亚新南威尔士州99,910名丙肝通知者,链接住院与死亡数据,评估直接抗病毒药物(DAA)时代前后丙肝相关失代偿性肝硬化、肝细胞癌(HCC)住院及肝相关和全因死亡趋势。结果显示DAA时代失代偿性肝硬化和肝相关死亡数量下降,HCC和全因死亡趋于平稳,酒精使用障碍仍是肝相关死亡独立相关因素。
要点
- DAA时代失代偿性肝硬化诊断和肝相关死亡数量每6个月分别下降(IRR 0.97和0.96)。
- DAA时代HCC诊断和全因死亡数量趋于平稳(IRR 1.00和1.01)。
- 酒精使用障碍与肝相关死亡独立相关(IRR 3.35,95%CI 3.14-3.58)。
核心结论
- 在澳大利亚新南威尔士州DAA时代,肝病发病率和死亡率急剧下降,但酒精使用障碍仍是HCV相关肝病负担的主要贡献因素,强调需处理合并症。
研究设计与样本
- 研究链接1993-2016年HCV通知、2001-2017年住院和1995-2017年死亡数据,使用分段泊松回归和泊松回归评估DAA时代影响及肝相关死亡相关因素,纳入99,910名HCV通知者。
主要发现
- 在99,910名HCV通知者中,3.8%诊断为失代偿性肝硬化,1.8%诊断为HCC,3.3%死于肝相关死亡,10.5%死于全因死亡。
- DAA前时代,每6个月失代偿性肝硬化、HCC诊断、肝相关死亡和全因死亡数量持续增加,IRR分别为1.04(95%CI 1.04-1.05)、1.08(95%CI 1.07-1.08)、1.07(95%CI 1.06-1.07)和1.05(95%CI 1.04-1.05)。
- DAA时代,每6个月失代偿性肝硬化诊断和肝相关死亡数量下降,IRR分别为0.97(95%CI 0.95-0.99)和0.96(95%CI 0.94-0.98);HCC诊断和全因死亡数量趋于平稳,IRR分别为1.00(95%CI 0.97-1.03)和1.01(95%CI 1.00-1.02)。
- DAA时代,诊断为失代偿性肝硬化和HCC的患者中酒精使用障碍常见(分别有65%和46%有酒精使用障碍史)。
- 酒精使用障碍与肝相关死亡独立相关(IRR 3.35;95%CI 3.14-3.58)。
临床怎么用
- 作者指出,酒精使用障碍仍是HCV相关肝病负担的主要贡献因素,强调需要处理合并症,包括改善丙肝患者中重度酒精使用的管理。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Population-level evidence for the impact of direct-acting antiviral (DAA) therapy on hepatitis C virus (HCV)-related disease burden is lacking. We aimed to evaluate trends in HCV-related decompensated cirrhosis and hepatocellular carcinoma (HCC) hospitalisation, and liver-related and all-cause mortality in the pre-DAA (2001-2014) and DAA therapy (2015-2017) eras in New South Wales, Australia. METHODS: HCV notifications (1993-2016) were linked to hospital admissions (2001-2017) and mortality (1995-2017). Segmented Poisson regressions and Poisson regression were used to assess the impact of DAA era and factors associated with liver-related mortality, respectively. RESULTS: Among 99,910 people with an HCV notification, 3.8% had a decompensated cirrhosis diagnosis and 1.8% had an HCC diagnosis, while 3.3% and 10.5% died of liver-related and all-cause mortality, respectively. In the pre-DAA era, the number of decompensated cirrhosis and HCC diagnoses, and liver-related and all-cause mortality consistently increased (incidence rate ratios 1.04 [95% CI 1.04-1.05], 1.08 [95% CI 1.07-1.08], 1.07 [95% CI 1.06-1.07], and 1.05 [95% CI 1.04-1.05], respectively) over each 6-monthly band. In the DAA era, decompensated cirrhosis diagnosis and liver-related mortality numbers declined (incidence rate ratios 0.97 [95% CI 0.95-0.99] and 0.96 [95% CI 0.94-0.98], respectively), and HCC diagnosis and all-cause mortality numbers plateaued (incidence rate ratio 1.00 [95% CI 0.97-1.03] and 1.01 [95% CI 1.00-1.02], respectively) over each 6-monthly band. In the DAA era, alcohol-use disorder (AUD) was common in patients diagnosed with decompensated cirrhosis and HCC (65% and 46% had a history of AUD, respectively). AUD was independently associated with liver-related mortality (incidence rate ratio 3.35; 95% CI 3.14-3.58). CONCLUSIONS: In the DAA era, there has been a sharp decline in liver disease morbidity and mortality in New South Wales, Australia. AUD remains a major contributor to HCV-related liver disease burden, highlighting the need to address comorbidities. LAY SUMMARY: Rising hepatitis C-related morbidity and mortality is a major public health issue. However, development of highly effective medicines against hepatitis C (called direct-acting antivirals or DAAs) means hepatitis C could be eliminated as a public health threat by 2030. This study shows a sharp decline in liver disease morbidity and mortality since the introduction of DAAs in New South Wales, Australia. Despite this, heavy alcohol use remains an important risk factor for liver disease among people with hepatitis C. To ensure that the benefits of new antiviral treatments are not compromised, management of major comorbidities, including heavy alcohol use must improve among people with hepatitis C.
引用
- Alavi M, Law MG, Valerio H, et al. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia. J Hepatol. 2019. PMID: 31078544. doi:10.1016/j.jhep.2019.04.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。